{
    "clinical_study": {
        "@rank": "132706", 
        "arm_group": [
            {
                "arm_group_label": "Arm1: control group", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Received 250 ml of a 5% dextrose solution as placebo drug"
            }, 
            {
                "arm_group_label": "Arm 2: diltiazem group", 
                "arm_group_type": "Experimental", 
                "description": "Received a 100 \u00b5g/kg bolus followed by a 0.3 \u00b5g/kg infusion diluted in 250 ml  of 5% dextrose solution"
            }, 
            {
                "arm_group_label": "Arm 3: acetylcystein group", 
                "arm_group_type": "Experimental", 
                "description": "Received 150 mg/kg acetylcystein diluted in 250 ml of 5% dextrose solution"
            }, 
            {
                "arm_group_label": "Arm 4: diltiazem and acetylcystein group", 
                "arm_group_type": "Experimental", 
                "description": "Received a combination of drug :\nbolus diltiazem 100 \u00b5g/kg followed by a 0.3 \u00b5g/kg infusion diluted in 125 ml of a 5% dextrose solution and 150 mg/kg acetylcystein diluted in 125 ml of 5% dextrose solution"
            }
        ], 
        "brief_summary": {
            "textblock": "Less oxidative stress occurs during off-pump than on-pump coronary artery bypass graft\n      (CABG) surgery but warm ischaemia-reperfusion injury may occur following transient coronary\n      artery clamping. The aim of this study was to compare the preventive effects of diltiazem\n      and N-acetylcysteine (NAC), alone or in combination, on biomarkers of myocardial damage and\n      oxidative stress during off-pump CABG surgery."
        }, 
        "brief_title": "Ischaemia-r\u00e9perfusion During the Coronary Surgery With Beating Heart", 
        "condition": "Ischaemia-reperfusion Injury", 
        "condition_browse": {
            "mesh_term": [
                "Ischemia", 
                "Reperfusion Injury", 
                "Wounds and Injuries"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age included between 60 and 80 years\n\n        Exclusion Criteria:\n\n          -  Age < 60 or > 80 years\n\n          -  Pregnancy\n\n          -  The allergy in used medicines (N-ac\u00e9tylcyst\u00e9ine, Diltiazem)\n\n          -  Presence of a pathology valvulaire associated\n\n          -  Urgency\n\n          -  Unstable angor\n\n          -  Bypass as a matter of urgency\n\n          -  Recours perop\u00e9ratoire to a CEC\n\n          -  FE < 0,40\n\n          -  BAV of the 2nd and 3rd not sailed degree\n\n          -  fibrillation or flutter little finger."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "60 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 27, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01771978", 
            "org_study_id": "2276"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm1: control group", 
                "description": "Received 250 ml of a 5% dextrose solution as placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "placebo group"
            }, 
            {
                "arm_group_label": "Arm 2: diltiazem group", 
                "description": "Received a 100 \u00b5g/kg bolus followed by a 0.3 \u00b5g/kg infusion diluted in 250 ml  of 5% dextrose solution", 
                "intervention_name": "Diltiazem", 
                "intervention_type": "Drug", 
                "other_name": "Diltiazem group"
            }, 
            {
                "arm_group_label": "Arm 3: acetylcystein group", 
                "description": "Received 150 mg/kg acetylcystein diluted in 250 ml of 5% dextrose solution", 
                "intervention_name": "Acetylcystein", 
                "intervention_type": "Drug", 
                "other_name": "Acetylcystein group"
            }, 
            {
                "arm_group_label": "Arm 4: diltiazem and acetylcystein group", 
                "description": "Received a combination of drug :diltiazem and acetylcystein\nbolus diltiazem 100 \u00b5g/kg followed by a 0.3 \u00b5g/kg infusion diluted in 125 ml of a 5% dextrose solution\n150 mg/kg acetylcystein diluted in 125 ml of 5% dextrose solution", 
                "intervention_name": "diltiazem and acetylcystein", 
                "intervention_type": "Drug", 
                "other_name": "Combined diltiazem and acetylcystein drug group"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Diltiazem"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "ischaemia-reperfusion injury", 
            "cardiac surgery", 
            "oxidative stress markers", 
            "troponin", 
            "diltiazem", 
            "acetylcystein"
        ], 
        "lastchanged_date": "January 16, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Strasbourg", 
                    "country": "France", 
                    "zip": "67091"
                }, 
                "name": "Department of Anaesthesiology"
            }
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "4", 
        "official_title": "Effects of Diltiazem and/or N-Ac\u00e9tylcyst\u00e9ine Versus Placebo on h\u00e9modynamiques and Biological Repercussions of the Ischaemia-r\u00e9perfusion During the Coronary Surgery With Beating Heart", 
        "overall_official": {
            "affiliation": "Strasbourg University Hospital, France", 
            "last_name": "Annick Steib, MD, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "France: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "February 2008", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Choosing as main biological variable rate cTnI cardiospecific, above the threshold of detection (0.3 mcg / L) in 40% of patients operated on a beating heart hoping to reduce this percentage to 10% as a result of treatment with diltiazem and N-acetylcysteine", 
            "measure": "Reduce the percentage 40% of patients operated on a beating heart to 10% as a result of treatment with diltiazem and N-acetylcysteine", 
            "safety_issue": "No", 
            "time_frame": "during ischaemia-reperfusion"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01771978"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "University Hospital, Strasbourg, France", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University Hospital, Strasbourg, France", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2002", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2008"
    }
}